Mavyret (glecaprevir and pibrentasvir)

Mavyret (known as Maviret in many international markets) is a breakthrough fixed-dose combination medication used for the treatment of chronic hepatitis C. It was developed by AbbVie, a research-based biopharmaceutical company. The medication consists of two direct-acting antiviral agents: glecaprevir, a protease inhibitor, and pibrentasvir, an NS5A inhibitor.

Mavyret was first approved by the U.S. Food and Drug Administration in 2017. As a globally distributed prescription drug, its manufacturing takes place across AbbVie's sophisticated supply chain, primarily involving high-tech facilities in the United States, Ireland, and Germany. The brand remains under the exclusive ownership of AbbVie, which continues to lead innovation in the immunology and virology sectors.